EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Fludarabine, cyclophosphamide, and rituximab as first‐line treatment in patients with chronic lymphocytic leukemia: A long‐term analysis of the German CLL Study Group (GCLLSG) registry

Nadine Kutsch iD, Adam Giza, Sandra Robrecht, Janina Stumpf, Anno Federhen, Andrea Stoltefuß, Ursula Vehling-Kaiser, Michael Koenigsmann, Eugen Tausch, Christof Schneider, Stephan Stilgenbauer, Thomas Illmer und 13 weitere

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14220 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Nadine Kutsch und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologn…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Rituximab, Vidarabine, Cyclophosphamide. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long‐term data of chronic lymphocytic leukemia (CLL) patients with favorable risk who were treated with fludarabine, cyclophosphamide, and rituximab (FCR) within clinical trials show good efficacy. We here report long‐term data collected within the GCLLSG registry. Altogether, 417 CLL patients who received first‐line treatment with FCR were analyzed, of which 293 (70.3%) were treated outside of clinical trials. The median observation time from first‐line was 95.8 (interquartile range 58.7–126.8) months. Focusing on data of 194 (46.5%) patients who received FCR first‐line treatment after 2013 (start of data collection within GCLLSG registry), responses were documented in 85% of the patients, non‐responses in 15%, and for 3.6% the assessment was missing. Median event‐free survival (EFS, time until disease progression, subsequent treatment, or death) was 60.2 months with a 5‐year EFS‐rate of 50.6%. Patients with higher‐risk disease, characterized by unmutated IGHV ( N = 78), had a median EFS of 45.4 months with a 5‐year EFS rate of 36.3%, while the median EFS was 77.5 months with a 5‐year EFS rate of 60.3% in patients with mutated IGHV ( N = 40). Median overall survival was not reached with a 5‐year survival rate of 92.7%. In summary, first‐line FCR was associated with long EFS, especially in patients exhibiting a mutated IGHV status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellRituximabVidarabineCyclophosphamideRegistriesAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAgedMiddle AgedTreatment OutcomeGermanyAged, 80 and overAdult

Stichwörter der Autor:innen

CLLFCRGCLLSG registry

Substanzen

RituximabVidarabinefludarabineCyclophosphamide

Autor:innen und Institutionen

  • Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Evangelisches Krankenhaus Hamm, Hamm, Germany.
  • ÜBAG MVZ Dr. Vehling-Kaiser GmbH, Landshut, Germany.
  • Onkologisches Ambulanzzentrum Hannover.
  • Division of CLL, Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany.
  • Gemeinschaftspraxis Hämatologie-Onkologie, Dresden, Germany.

ORCID-Profile: Nadine Kutsch, Julia von Tresckow

Zitieren

APA

Kutsch, N., Giza, A., Robrecht, S., Stumpf, J., Federhen, A., Stoltefuß, A., Vehling-Kaiser, U., Koenigsmann, M., Tausch, E., Schneider, C., Stilgenbauer, S., Illmer, T., Schlag, R., Dörfel, S., Gaska, T., Kiehl, M., Müller-Hagen, S., Moorahrend, E., Linde, H., …, & Fink, A. M. (2024). Fludarabine, cyclophosphamide, and rituximab as first‐line treatment in patients with chronic lymphocytic leukemia: A long‐term analysis of the German CLL Study Group (GCLLSG) registry. European Journal of Haematology. https://doi.org/10.1111/ejh.14220

Vancouver

Kutsch N, Giza A, Robrecht S, Stumpf J, Federhen A, Stoltefuß A, et al. Fludarabine, cyclophosphamide, and rituximab as first‐line treatment in patients with chronic lymphocytic leukemia: A long‐term analysis of the German CLL Study Group (GCLLSG) registry. European Journal of Haematology. 2024. doi:10.1111/ejh.14220

BibTeX
@article{Kutsch2024,
  author = {Kutsch, Nadine and Giza, Adam and Robrecht, Sandra and Stumpf, Janina and Federhen, Anno and Stoltefuß, Andrea and Vehling-Kaiser, Ursula and Koenigsmann, Michael and Tausch, Eugen and Schneider, Christof and Stilgenbauer, Stephan and Illmer, Thomas and Schlag, Rudolf and Dörfel, Steffen and Gaska, Tobias and Kiehl, Michael and Müller-Hagen, Sigrun and Moorahrend, Enno and Linde, Hartmut and Schlenska-Lange, Anke and von Tresckow, Julia and Fischer, Kirsten and Eichhorst, Barbara and Hallek, Michael and Fink, Anna Maria},
  title = {Fludarabine, cyclophosphamide, and rituximab as first‐line treatment in patients with chronic lymphocytic leukemia: A long‐term analysis of the German CLL Study Group (GCLLSG) registry},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14220}
}
Kostenlos starten →